{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-VAAC35VN/02dfea46-1674-4f9b-9a3e-1691599678b6/HTML","dcterms:extent":"26 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-VAAC35VN/83daa665-f743-4db0-be77-6fae43d3ea5f/PDF","dcterms:extent":"136 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-VAAC35VN/14402535-317e-47f9-badd-c75e6e4523fb/TEXT","dcterms:extent":"25 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-VAAC35VN","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2005","dc:creator":"Černe, Darko","dc:format":[{"@xml:lang":"sl","#text":"številka:4"},{"@xml:lang":"sl","#text":"5 strani"},{"@xml:lang":"sl","#text":"letnik:56"},{"@xml:lang":"sl","#text":"str. 254-258"}],"dc:identifier":["ISSN:0014-8229","COBISSID:1883505","URN:URN:NBN:SI:doc-VAAC35VN"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"en","#text":"diabetes mellitus"},{"@xml:lang":"sl","#text":"klinična biokemija"},{"@xml:lang":"sl","#text":"ledvične bolezni"},{"@xml:lang":"sl","#text":"sladkorna bolezen"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Klinična biokemija pri obravnavi ledvičnih zapletov sladkorne bolezni|"},"dc:description":[{"@xml:lang":"sl","#text":"Here we describe the importance of medical biochemistry in diagnosis and monitoring of renal complications of diabetes mellitus, such as diabetic nephropathy, renal artery atherosclerosis, pielonephritis and papillary necrosis. Microalbuminuria (early increase of albumin concentration in urine) is nowadays the strongest and the most frequently used prognostic marker of advanced diabetic nephropathy and diagnostic indicator of an early disease, therefore, measurement of albumin concentration in urine of diabetic patients should be regularly measured according to the recommended guidelines. Von Willebrand factor activity in plasma and renal functional reserve, nowadays used in research only, may become in future a part of a routine laboratory diagnostics of diabetic nephropathy. In renal artery atherosclerosis laboratory diagnostics has only minor importance and is limited to analysis ofĆconventionalĆ parameters for atherosclerotic risk stratification (lipids, lipoproteins, C-reactive protein, homocysteine). In diagnosis and treatment ofpielonephritis and papillary necrosis basic urinalysis has important role and should be regularly performed. Our overview may be of help when choosing appropriate laboratory assays for diagnosis and monitoring of renal complications of diabetes mellitus"},{"@xml:lang":"sl","#text":"V članku je predstavljen pomen klinične biokemije pri obravnavi ledvičnih zapletov sladkorne bolezni, kot so diabetioena nefropatija, ateroskleroza renalnih arterij, pielonefritis in papilarna nekroza. Mikroalbuminurija (zgodnji porast koncentracije albumina v urinu) je danes najmočnejši in najpogosteje uporabljen napovednik razvoja napredovane diabetične nefropatije oziroma zgodnji označevalec že prisotne bolezni, zato se mora koncentracija albumina v urinu sladkornih bolnikov meriti redno po uveljavljenih priporočilih. Aktivnost von Willebrandovega faktorja v plazmi in renalna funkcijska rezerva, ki se danes uporabljata predvsem v raziskovalne namene, bi v prihodnosti lahko postali sestavni del zahtevnejše laboratorijske obravnave diabetioene nefropatije. Pri odkrivanju aterosklerozerenalnih arterij laboratorijska diagnostika nima pomembnejše vloge, z izjemo analize priznanih dejavnikov tveganja za razvoj ateroskleroze (lipidi, lipoproteini, C-reaktivni protein, homocistein). Pri laboratorijski obravnavi pielonefritisa in papilarne nekroze imajo osnovne preiskave urina pomembno vlogo, zato se morajo pri ogroženih bolnikih izvajati redno. Namen prispevka je pomagati pri izbiri in pravilni uporabi primernih laboratorijskih preiskav za odkrivanje in sledenje ledvičnih zapletov sladkorne bolezni"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-VAAC35VN","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-VAAC35VN"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-VAAC35VN/83daa665-f743-4db0-be77-6fae43d3ea5f/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-VAAC35VN/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-VAAC35VN"}}}}